Encontrados 4 documentos, a visualizar página 1 de 1
Clinical, histological and molecular profiling of different stages of alcohol-r...
Ventura-Cots, Meritxell; Argemi, Josepmaria; Jones, Patricia D; Lackner, Carolin; El Hag, Mohamed; Abraldes, Juan G; Alvarado, Edilmar; Clemente, AnaObjective: Alcohol-related liver disease (ALD) ranges from never-decompensated ALD (ndALD) to the life-threatening decompensated phenotype, known as alcohol-related hepatitis (AH). A multidimensional study of the clinical, histological and molecular features of these subtypes is lacking. Design: Two large cohorts of patients were recruited in an international, observational multicentre study: a retrospective co...
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projection...
Huang, Daniel Q.; Mathurin, Philippe; Cortez-Pinto, Helena; Loomba, RohitHeavy alcohol consumption is a major cause of morbidity and mortality. Globally, alcohol per-capita consumption rose from 5.5 litres in 2005 to 6.4 litres in 2016 and is projected to increase further to 7.6 litres in 2030. In 2019, an estimated 25% of global cirrhosis deaths were associated with alcohol. The global estimated age-standardized death rate (ASDR) of alcohol-associated cirrhosis was 4.5 per 100,000 ...
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round ...
Avila, Matias A.; Dufour, Jean-François; Gerbes, Alexander L.; Zoulim, Fabien; Bataller, Ramon; Burra, Patrizia; Cortez-Pinto, Helena; Gao, BinAlcohol-related liver disease (ALD), which includes a range of disorders of different severity and is one of the most prevalent types of liver disease worldwide, has recently regained increased attention. Among other reasons, the realisation that any alcohol intake, regardless of type of beverage represents a health risk, and the new therapeutic strategies tested in recently published or undergoing clinical tri...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim an...
Younossi, Zobair M.; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M.; Goodman, Zachary; Bedossa, Pierre; Geier, AndreasBackground: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-contro...